Citation: Journal of Pediatric & Adolescent Gynecology. 2018 Jun 19; Journal of Pediatric & Adolescent Gynecology. 31(5):503-508, 2018 Oct..Journal: Journal of pediatric and adolescent gynecology.Published: 2018ISSN: 1083-3188.Full author list: Hennessey CA; Patel VK; Tefera EA; Gomez-Lobo V; Hennessey CA; Patel VK; Tefera EA; Gomez-Lobo V.UI/PMID: 29932972.Institution(s): MedStar Health Research Institute | MedStar Washington Hospital CenterDepartment(s): Obstetrics and Gynecology/Pediatric and AdolescentActivity type: Journal Article.Medline article type(s): Journal ArticleOnline resources: Click here to access onlineDigital Object Identifier: https://dx.doi.org/10.1016/j.jpag.2018.06.007 (Click here)Abbreviated citation: J Pediatr Adolesc Gynecol. 2018 Jun 19; J Pediatr Adolesc Gynecol. 31(5):503-508, 2018 Oct.Local Holdings: Available online through MWHC library: 2002 - present.Abstract: STUDY OBJECTIVE: Our goal was to describe the period prevalence of VTE and characterize adolescent female patients diagnosed with VTE by describing their age, race, and number of comorbidities. Adolescent females with estrogen exposure were of particular interest since estrogen-containing contraception increases the risk of VTE.Abstract: DESIGN, SETTING, PARTICIPANTS: We queried the Pediatric Health Information System database for International Classification of Diseases, Ninth/Tenth Revision, Clinical Modification codes to identify females aged twelve to eighteen years old diagnosed with a VTE or PE from April 2006 - March 2016 in the United States. Patient demographics and comorbidities were also analyzed. We divided our study population into two five-year groups and calculated the change in period prevalence of VTE between those groups.Abstract: MAIN OUTCOME MEASURES: Primary diagnosis of VTE in the extremities, or PE.Abstract: RESULTS: The period prevalence of VTE increased from 2.3 adolescent females per 10,000 hospitalized children (Group 1) to 3.3 per 10,000 (Group 2), representing a statistically significant increase of 0.010% (p-value = <0.001). Caucasians and Blacks were most commonly affected. The number of girls affected increased steadily from ages twelve to sixteen and the majority (59.6%) had four or more comorbidities. In patients (N=32) with estrogen exposure, greater than 96% had one or more co-morbidity in addition to estrogen exposure.Abstract: CONCLUSION: Pediatric health care providers should be aware that the period prevalence of VTEs in adolescent females is increasing. Those with a history of estrogen exposure rarely develop VTEs from estrogen alone and they typically have multiple co-morbidities.Abstract: Copyright (c) 2018. Published by Elsevier Inc.